OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

Inlexisertib

aka DCC-3116

Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer.